LGALS3 and COVID-19: Inhibition of Gal-3 significantly reduces the levels of these cytokines, and so may show promise in reducing inflammatory sequelae associated with COVID-19 (De Biasiet al., 2020;Kalfaogluet al., 2020;Liuet al., 2020).